• 1
    Yamanishi T, Takei K, Tobe T, Ueda T, Ito H, Yasuda K. Transurethral holmium:YAG laser prostatectomy using a side-firing fiber for bladder outlet obstruction due to benign prostatic enlargement: urodynamic evaluation of surgical outcome. Eur. Urol. 2001; 39: 54450.
  • 2
    Arnold EP. Tamsulosin in men with confirmed bladder outlet obstruction: a clinical and urodynamic analysis from a single center in New Zealand. BJU Int. 2001; 87: 2431.
  • 3
    Yamanishi T, Yasuda K, Sakakibara R, Hattori T, Tojo M. Effectiveness of terazosin, an alpha1-blocker, on bladder neck obstruction as assessed by urodynamic hydraulic energy. BJU Int. 2000; 85: 24953.
  • 4
    Yasuda K, Yamanishi T, Tojo M, Nagashima K, Akimoto S, Shimazaki J. Effect of naftopidil on urethral obstruction in benign prostatic hyperplasia: assessment by urodynamic studies. Prostate 1994; 25: 4652.
  • 5
    Yasuda K, Yamanishi T, Kawabe K, Oshima H, Morita T. The effect of urapidil on neurogenic bladder: a placebo controlled double-blind study. J. Urol. 1996; 156: 112530.
  • 6
    Schulman CC, Lock TMTW, Buzelin JM, Boeminghaus F, Stephenson TP, Talja M. Long-term use of tamsulosin to treat lower urinary symptoms/benign prostatic hyperplasia. J. Urol. 2001; 166: 135863.
  • 7
    Takei R, Ikegaki I, Shibata K, Tsujimoto G, Asano T. Naftopidil, a novel α1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human α1-adrenoceptors. Jpn J. Pharmacol. 1999; 79: 44754.
  • 8
    Muramatsu I, Yamanaka K, Kigoshi S. Pharmacological profile of the novel α-adrenoceptor antagonist KT-611 (naftopidil). Jpn J. Pharmacol. 1991; 55: 3918.
  • 9
    Bales GT, Christiano AP, Kirsh EJ, Gerber GS. Phytotherapeutic agents in the treatment of lower urinary tract symptoms: a demographic analysis of awareness and use at the University of Chicago. Urology 1999; 54: 869.
  • 10
    Berges RR, Kassen A, Senge T. Treatment of symptomatic benign prostatic hyperplasia with β-sitosterol: an 18-month follow-up. BJU Int. 2000; 85: 8426.
  • 11
    Buck AC. Phytotherapy for the prostate. Br. J. Urol. 1996; 78: 32536.
  • 12
    Chatelain C, Autet W, Brackman F. Comparison of once and twice daily dosage forms of Pygeum africanum extract in patients with benign prostatic hyperplasia: a randomized, double-blind study, with long-term open label extension. Urology 1999; 54: 4738.
  • 13
    Lowe FC, Fagelman E. Phytotherapy in the treatment of benign prostatic hyperplasia: an update. Urology 1999; 53: 6718.
  • 14
    Gerber GS, Zagaja GP, Bales GT. Saw palmetto (Serena repens) in men with lower urinary tract symptoms: effects on urodynamic parameters and voiding symptoms. Urology 1998; 51: 10037.
  • 15
    Ishigooka M, Hashimoto T, Hayami S, Tomaru M, Nakada T, Mitobe K. Clinical and retrospective evaluation of eviprostat: a non-hormonal and non-neuropharmacological agent for benign prostatic hyperplasia. Int. Urol. Nephrol. 1995; 27: 616.
  • 16
    Boyle P, Robertson C, Lowe F, Roehrborn C. Meta-analysis of clinical trials of Permixon in the treatment of symptomatic benign prostatic hyperplasia. Urology 2000; 55: 5339.
  • 17
    Abrams P, Cardozo L, Fall M et al. The standardization of terminology of lower urinary tract function: report from the standardization sub-committee of the International Continence Society. Neurourol. Urodyn. 2002; 21: 16778.
  • 18
    Homma Y, Kawabe K, Tsukamoto T et al. Estimate criteria for efficacy of treatment in benign prostatic hyperplasia. Int. J. Urol. 1996; 3: 26773.
  • 19
    Roehrborn CG, Abbou CC, Allona-Almagro A et al. BPH: Clinical research criteria. In: DenisL, GriffithsK, KhouryS et al. (eds). Proceedings of the 4th International Consultation of Benign Prostatic Hyperplasia. July 2–5 1997, Paris, France. Plymbridge Distributors Ltd, Plymouth, 1998; 43791.
  • 20
    Sasaki Y, Fukui T, Kimura Y, Ogasawara T, Ukai Y. Eviprostat, a drug for benign prostatic hyperplasia, ameliorates the urodynamic disturbance in rats with cystitis and chronic urethral obstruction. Jpn Pharmacol. Ther. 2000; 28: 46371.
  • 21
    Gleason DM, Bottaccini MR. Effect of terazosin on urine storage and voiding in the aging male with prostatism. Neurourol. Urodyn. 1994; 13: 112.
  • 22
    Malloy BJ, Price DT, Price RR et al. α1-Adrenergic receptor subtypes in human detrusor. J. Urol. 1998; 160: 93743.
  • 23
    Hampel C, Dolber PC, Smith MP et al. Modulation of bladder α1-adrenergic receptor subtype expression by bladder outlet obstruction. J. Urol. 2002; 167: 151321.
  • 24
    Schwinn DA. The role of α1-adrenergic receptor subtypes in lower urinary tract symptoms. BJU Int. 2001; 88 (Suppl. 2): 2734.
  • 25
    Sugaya K, Nishijima S, Miyazato M, Ashitomi K, Hatano T, Ogawa Y. Effects of intrathecal injection of tamsulosin and naftopidil, alpha-1A and –1D adrenergic receptor antagonists, on bladder activity in rats. Neurosci. Lett. 2002; 328: 746.
  • 26
    Yoshiyama M, DeGroat WC. Role of spinal α1-adrenoceptor subtypes in the bladder reflex in anesthetized rats. Am. J. Physiol. 2001; 280: R141419.
  • 27
    Yoshimura N, Chancellor MB. Current and future pharmacological treatment for overactive bladder. J. Urol. 2002; 168: 1897913.
  • 28
    Abbou CC, Hozneck A, McCarthy C. Alfuzosin, a uroselective alpha-1-blocker versus Pygeum africanum, a plant extract: a randomized controlled trial in patients with symptomatic benign prostatic hypertrophy (BPH). Eur. Urol. 1996; 30 (Suppl. 2): 61.
  • 29
    Debuyne F, Koch G, Boyle P et al. Comparison of a phytotherapeutic agent (Permixon) with an α-blocker (tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Eur. Urol. 2002; 41: 497507.